Luminex Plc · CSELK:LUMX.N0000

Luminex — 34th Annual J.P. Morgan Healthcare Conference (January 2016)

21 slides from Luminex's conference presentation, Jan 11, 2016

  1. Slide 1: 34th Annual J.P. Morgan Healthcare Conference

    34th Annual J.P. Morgan Healthcare Conference NACHUM “HOMI” SHAMIR President and Chief Executive Officer

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement 2 Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: o

  3. Slide 3: Luminex: A Growth Story

    LUMINEX A Growth Story 3 GLOBAL REACH 800+ Employees worldwide Austin, Texas - headquarters ATTRACTIVE Markets Multi-billion dollar life science and clinical diagnostic markets DIFFERENTIATED Technology Hardware/test menu addressing the needs of our clinical and research customers; 325+ issued paten

  4. Slide 4: Building momentum through focus, innovation and execution

    LUMINEX Building momentum through focus, innovation and execution 4 NEW LEADERSHIP Homi Shamir joins as CEO REALIGNED Focus and priorities STRONG FINANCIAL RESULTS Guidance raised EXPANSION MDx sales force FDA CLEARED ARIES®+HSV 1&2 FDA Cleared, Launched at AMP Conference FDA CLEARED NxTAG RPP 2014

  5. Slide 5: Four Pillars of Growth

    LUMINEX Four Pillars of Growth PARTNERS MDx ARIES® FINANCIAL STRENGTH solid and profitable direct to customer growth accelerator new MDx platform strong balance sheet, no debt and strong cash flow 5

  6. Slide 6: Partners Business Update

    5 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science PARTNERS Business Update

  7. Slide 7: A Solid Foundation Through Our Partners

    A Solid Foundation Through Our PARTNERS 7 50% OUR PARTNERS account for ~50% of our business 2/3 DIAGNOSTICS approximately two thirds of total revenue comes from Dx

  8. Slide 8: Partner Channel: Solid & Profitable

    PARTNER CHANNEL Solid & Profitable 8 Strong Profitability & Cash Generator On track 2015 end-user sales to exceed $500M Growth Expectations 5-8% Adjusted for discrete partner event

  9. Slide 9: Unique, Proprietary Platforms and Large Number of Cumulative Shipments

    3,400 4,980 6,770 8,680 10,740 12,500+ 2005 2007 2009 2011 2013 2015E Unique, Proprietary Platforms and LARGE Number of Cumulative Shipments 9 LUMINEX 100/200 accounts for ~10,000 systems sold to date MAGPIX® accounts for ~2,000 systems FLEXMAP 3D® accounts for ~500 systems CAGR: ’05-’15E = 14%

  10. Slide 10: MDx Business Update: Molecular Diagnostics Franchise

    Business Update Molecular Diagnostics Franchise 8 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science MDx Business Update

  11. Slide 11: Current MDx Portfolio

    Current MDx Portfolio 11 INFECTIOUS DISEASES GENETICS Pharmacogenetics xTAG® CYP2D6 (Personalized Medicine) xTAG® CYP2C19 Cystic Fibrosis xTAG® CF Respiratory xTAG® RVP xTAG® RVP Fast NxTAG® RPP Gastrointestinal xTAG® GPP Women’s Health MultiCode® HSV 1&2

  12. Slide 12: Molecular Diagnostics Growth Driver

    12 ) • Insert 2015 data in chart and boxes PARTNERS solid and profitable MDx growth accelerator ARIES new MDx Platform FINANCIAL Strong balance sheet and no debt MOLECULAR DIAGNOSTICS Growth Driver 2014 Revenue ~$88M Growth Expectations (ex-ARIES®) ~12%+ Expected 2015 Assay Revenue of $100M+ 2016P 2

  13. Slide 13: ARIES Business Update

    12 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science ARIES® Business Update

  14. Slide 14: ARIES: What Labs are Saying

    14 “…ARIES® enables our lab to run user-defined protocols with SIGNIFICANTLY LESS HANDS-ON TIME.” ARIES® What Labs are Saying “a GAME-CHANGER for our workflow!!” “ARIES® is ROBUST, FLEXIBLE, with the right throughput.” “The ability to mix and match assays in the same run is a GREAT FIT FOR OUR WORKF

  15. Slide 15: ARIES: Scalable, Sample to Answer MDx Platform

    ARIES® Scalable, Sample to Answer MDx Platform 15 CHALLENGES FOR LABS • Sample switching and misdiagnosis • Varying testing platforms • Scarcity of trained personnel • High volume of reports • Limited bench space ARIES® SOLUTION • Position Independent Results minimizes sample switching • Compelling

  16. Slide 16: ARIES: What Labs are Saying

    ARIES® What Labs are Saying 16 Stephen Young, Ph.D. Scientific Director - Infectious Disease, TriCore Reference Laboratories

  17. Slide 17: Expanding Downstream With ARIES

    INCREMENTAL MARKET OPPORTUNITY Expanding Downstream With ARIES® 17 Source: Mdxi Market Diagnostics Int’l, 2013 Emmes: 1,000 U.S. laboratory survey, Scientia Analysis, AHA Registered U.S. Hospitals, CMS CLIA KEY POSITIONING • Access to Attractive, Fast Growing Markets • Simple, Easy to Use Solutions

  18. Slide 18: Financial Highlights

    Financial Highlights 18 | © Copyright 2015 Luminex Corporation | Breakthrough solutions to improve health and advance science FINANCIAL STRENGTH Highlights

  19. Slide 19: Strong Financial Performance

    [1] Non-GAAP Operating margin for years 2010-2015 exclude litigation fees, restructuring, severance, and settlement of distributor agreements STRONG Financial Performance 19 OTHER HIGHLIGHTS • Significant Operating Leverage & Profitability - Strong Free Cash Flow ($35+M in 2015) - No Debt - $140+M i

  20. Slide 20: Exciting Future: Four Pillars of Growth

    EXCITING FUTURE Four Pillars of Growth 20 PARTNERS MDx ARIES® FINANCIAL STRENGTH 5-8% Revenue Growth High 20% Op Margins Double Digit Revenue Growth Improving Profitability 100 Placements by YE16 Rapid Menu Expansion Healthy Cash Balance No Debt M&A ARIES® V1+

  21. Slide 21: Thank You

    Luminex. Thank You

Luminex — 34th Annual J.P. Morgan Healthcare Conference (January 2016) on 6ix